Dan Skovronsky, Eli Lilly CSO

An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lil­ly spot­light­ed a suc­cess for one of 3 dos­es of their close­ly-watched Covid-19 an­ti­body drug Wednes­day morn­ing. But an­a­lysts quick­ly high­light­ed some ob­vi­ous anom­alies that could come back to haunt the phar­ma gi­ant as it looks for an emer­gency use au­tho­riza­tion to launch mar­ket­ing ef­forts.

The phar­ma gi­ant re­port­ed that LY-CoV555, de­vel­oped in col­lab­o­ra­tion with Ab­Cellera, sig­nif­i­cant­ly re­duced the rate of hos­pi­tal­iza­tion among pa­tients who were treat­ed with the an­ti­body. The drug arm of the study had a 1.7% hos­pi­tal­iza­tion rate, com­pared to 6% in the con­trol group, mark­ing a 72% drop in risk.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.